» Articles » PMID: 37727787

Electroacupuncture Alleviates Ulcerative Colitis by Targeting CXCL1: Evidence from the Transcriptome and Validation

Overview
Journal Front Immunol
Date 2023 Sep 20
PMID 37727787
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We aimed to use transcriptomics, bioinformatics analysis, and core gene validation to identify the core gene and potential mechanisms for electroacupuncture (EA) treatment of ulcerative colitis (UC).

Materials And Methods: EA was performed in mice after induction of UC dextran sodium sulfate. Body weight, disease activity index (DAI), colon length, and hematoxylin-eosin of the colon tissue were used to evaluate the effects of EA. Mice transcriptome samples were analyzed to identify the core genes, and further verified with human transcriptome database; the ImmuCellAI database was used to analyze the relationship between the core gene and immune infiltrating cells (IICs); and immunofluorescence was used to verify the results.

Results: EA could reduce DAI and histological colitis scores, increase bodyweight and colon length, and improve the expression of local and systemic proinflammatory factors in the serum and colon of UC mice. Eighteen co-differentially expressed genes were identified by joint bioinformatics analyses of mouse and human transcriptional data; was the core gene. EA affected IICs by inhibiting expression and regulated the polarization of macrophages by affecting the Th1 cytokine IFN-γ, inhibiting the expression of CXCL1.

Conclusions: CXCL1 is the target of EA, which is associated with the underlying immune mechanism related to Th1 cytokine IFN-γ.

Citing Articles

Quercetin alleviates ulcerative colitis through inhibiting CXCL8-CXCR1/2 axis: a network and transcriptome analysis.

Jiang Z, Yan M, Qin Y, Liu Z, Duan Y, Wang Y Front Pharmacol. 2024; 15:1485255.

PMID: 39717557 PMC: 11663639. DOI: 10.3389/fphar.2024.1485255.


Insights of Expression Profile of Chemokine Family in Inflammatory Bowel Diseases and Carcinogenesis.

Zhang Y, Jin Y, Wang Y, Wang S, Niu Y, Ma B Int J Mol Sci. 2024; 25(19).

PMID: 39409185 PMC: 11476924. DOI: 10.3390/ijms251910857.


Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.

Liu R, Luo Y, Ma J, Zhang Q, Sheng Y, Li J Front Pharmacol. 2024; 15:1444922.

PMID: 39355776 PMC: 11443704. DOI: 10.3389/fphar.2024.1444922.


Effects of acupuncture and moxibustion on ulcerative colitis: An overview of systematic reviews.

Wang D, Wang Q, Wang Y, Li T, Tian M Heliyon. 2024; 10(6):e27524.

PMID: 38510004 PMC: 10951544. DOI: 10.1016/j.heliyon.2024.e27524.

References
1.
Moin A, Sathyapalan T, Diboun I, Atkin S, Butler A . Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19. Sci Rep. 2021; 11(1):6428. PMC: 7979696. DOI: 10.1038/s41598-021-85760-y. View

2.
Nakamura K, Honda K, Mizutani T, Akiho H, Harada N . Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol. 2006; 12(29):4628-35. PMC: 4087824. DOI: 10.3748/wjg.v12.i29.4628. View

3.
De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K . Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. 2013; 121(24):4930-7. DOI: 10.1182/blood-2013-02-486217. View

4.
Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

5.
Dharmasiri S, Garrido-Martin E, Harris R, Bateman A, Collins J, Cummings J . Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease. Inflamm Bowel Dis. 2021; 27(10):1641-1652. PMC: 8522792. DOI: 10.1093/ibd/izab029. View